RIDDLE&CODE is Partnering With Influx Technology to Develop the Next Generation of its Drive&Stake Stack
2.6.2022 11:15:00 EEST | Business Wire | Press release
RIDDLE&CODE is partnering with Influx Technology LTD to develop the next generation of its Drive&Stake stack. This collaboration focuses on the further evolution of Drive&Stake hardware to transform vehicles into autonomous agents in a new era of mobility.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220602005047/en/
RIDDLE&CODE and Influx Technology are working together to build a powerful and flexible toolchain for original equipment manufacturer (OEM) developers in the automotive ACES (Automated, Connected, Electric and Shared) space to prototype peer-to-peer (P2P) blockchain-based solutions.
With three decades of experience and expertise in developing business-to-business (B2B) automotive embedded systems and deep in-vehicle communication protocol, Influx Technology will help RIDDLE&CODE create the next generation of Drive&Stake hardware.
"The goal is to manufacture a toolchain that reduces complexity and simplifies experimentation, enabling a more significant focus on value-added business models whilst ensuring vehicle safety and security," says Steve Ratheram, Senior R&D Engineer | Automotive Embedded at RIDDLE&CODE.
"Bringing together the automotive industry experience of Influx and the industrial Web3.0 vision of RIDDLE&CODE," says Minh Cao, Director of Mobility at RIDDLE&CODE, "the consortium engineers industry-grade hardware connected to a banking grade distributed ledger technology (DLT) infrastructure that finally transforms any vehicle into an autonomous economic agent and its drivers into data entrepreneurs."
About the Drive&Stake Consortium
The Drive&Stake consortium continues to realise its goal of creating decentralised and secure technologies, focusing on blockchain and cryptography. The D&S stack comprises reference hardware that connects vehicle embedded systems data to a secure exchange-to-exchange (E2E) data & token management system.
In addition to the new hardware, the Drive&Stake Consortium will lead to the following:
- The development of new data economies and vehicle lifecycle revenue streams
- The creation of secure provenance of trustful data
- The development of collaborative and decentralised data-driven business models
- The sharing of data and relevant information between competitors without revealing industry secrets
- Benefit from the network growth through a token-economical business model that governs and grows the network using incentives
- Gain access to the required backend technology stack to enable the rollout of all business processes on the platform in a regulatory compliant way
About RIDDLE&CODE
RIDDLE&CODE is Europe’s leading company for blockchain interface solutions. The company develops hardware and software stacks that combine the security of smart cards with blockchain and the Internet of Things (IoT). Together with its tier-one clients and partners, which include Daimler Mobility, BMW, Wien Energie and leading Dutch crypto exchange LiteBit, RIDDLE&CODE brings new business models to the fintech, energy, mobility and materials industries.
More information: www.riddleandcode.com
About Influx Technology
INFLUX TECHNOLOGY is the leading global name in vehicle CAN bus data logging providing innovative engineering solutions. Our global teams are dedicated to designing modular and flexible solutions that are intuitive to use, manufactured to a high standard with quality post-sale support.
More information: www.influxtechnology.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220602005047/en/
Contact information
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 19:19:00 EEST | Press release
Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease and lung cancer,” she added. “More broadly, it reinforces the agency’s science-based approach to evaluating products across the co
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 18:00:00 EEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 17:13:00 EEST | Press release
For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and more practical: what it takes to make a specific, high-stakes determination reliable, fast and affordable at scale. A vertical, domain-focused process, gro
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 17:08:00 EEST | Press release
Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d
Interactive Brokers Expands Access to Korean Equities with Launch of Nextrade ATS30.6.2026 17:00:00 EEST | Press release
Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced the launch of select Korean equities through Nextrade, South Korea's first Alternative Trading System (ATS). The addition of Nextrade builds on Interactive Brokers' earlier launch of the Korea Exchange (KRX), through which it became the first major US-based broker to provide global investors with direct access to Korean equities. Clients trading on Nextrade benefit from significantly extended trading hours and access to additional liquidity. Interactive Brokers has enabled IB SmartRouting℠ across both the Korea Exchange (KRX) and Nextrade, automatically routing orders to the venue offering the best price. This helps clients achieve best execution while providing greater flexibility and more opportunities to participate in one of Asia's most dynamic equity markets. Korea's equity market ranks among the top global exchanges by market capitalization and is home to world-leading companies such as Samsung Electr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom